Artivion (NYSE:AORT) Stock Price Up 5.7% – Still a Buy?

Shares of Artivion, Inc. (NYSE:AORT) traded up 5.7% during mid-day trading on Tuesday . The company traded as high as $29.35 and last traded at $29.94. 91,970 shares traded hands during trading, a decline of 84% from the average daily volume of 592,308 shares. The stock had previously closed at $28.32.

Analyst Upgrades and Downgrades

AORT has been the topic of a number of research analyst reports. Canaccord Genuity Group raised their target price on shares of Artivion from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday. Citizens Jmp lowered their price target on shares of Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a report on Friday, May 8th. Needham & Company LLC reiterated a “buy” rating and issued a $44.00 price target on shares of Artivion in a research note on Monday, July 20th. Citigroup reiterated a “market outperform” rating on shares of Artivion in a research note on Tuesday, July 21st. Finally, Stifel Nicolaus set a $45.00 price objective on Artivion in a report on Monday, June 1st. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $44.83.

Artivion Trading Up 4.6%

The business’s fifty day moving average is $24.44 and its 200-day moving average is $30.41. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.51 and a current ratio of 3.47. The firm has a market cap of $1.44 billion, a P/E ratio of -423.94 and a beta of 1.24.

Artivion (NYSE:AORT) last posted its earnings results on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. The firm had revenue of $125.76 million for the quarter, compared to analyst estimates of $119.99 million. Analysts predict that Artivion, Inc. will post 0.45 EPS for the current year.

Insider Buying and Selling at Artivion

In other Artivion news, SVP Jean F. Holloway sold 977 shares of Artivion stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $28.49, for a total transaction of $27,834.73. Following the transaction, the senior vice president directly owned 184,118 shares of the company’s stock, valued at approximately $5,245,521.82. The trade was a 0.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Andrew M. Green sold 44,001 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $20.70, for a total value of $910,820.70. Following the completion of the sale, the senior vice president owned 60,259 shares in the company, valued at $1,247,361.30. This trade represents a 42.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.30% of the company’s stock.

Hedge Funds Weigh In On Artivion

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Corient Private Wealth LP bought a new stake in Artivion in the second quarter valued at approximately $3,579,000. Bank of America Corp DE acquired a new position in shares of Artivion in the 2nd quarter worth approximately $11,717,000. Freestone Grove Partners LP bought a new stake in shares of Artivion in the 2nd quarter valued at $328,000. Jupiter Topco LLC bought a new stake in shares of Artivion in the 2nd quarter valued at $384,000. Finally, Parkman Healthcare Partners LLC acquired a new stake in shares of Artivion during the second quarter worth $3,122,000. 86.37% of the stock is owned by institutional investors and hedge funds.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.